Windtree Therapeutics (WINT)
(Delayed Data from NSDQ)
$3.79 USD
-0.03 (-0.81%)
Updated Jul 15, 2024 01:20 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
WINT 3.79 -0.03(-0.81%)
Will WINT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for WINT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for WINT
Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why
WINT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for WINT
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Windtree Therapeutics Regains Compliance with Nasdaq
Windtree Therapeutics regains compliance with Nasdaq, shares up
Windtree Therapeutics regains compliance with Nasdaq
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals among healthcare movers